NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

TB & Outbreaks Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB & Outbreaks Week

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Bacillus Calmette-Guerin Vaccines



Research results from Food & Drug Administration update knowledge of Bacillus calmette-guerin vaccines



March 3rd, 2009

According to a study from the United States, "In this study, the early pulmonary cytokine and chemokine responses in mice immunized with either BCG vaccine, a Delta secA2 mutant of Mycobacterium tuberculosis, or a DNA vaccine expressing an ESAT6-antigen 85B fusion protein and then aerogenically challenged with a low dose of M. tuberculosis were evaluated by PCR array."

"The cellular immune responses at day 10 postchallenge were essentially equivalent in the lungs of mice immunized with either the highly immunogenic BCG vaccine or the Delta secA2 M. tuberculosis mutant strain. Specifically, 12 immune biomolecules (including gamma interferon [IFN-gamma], interleukin-21...


Source: TB & Outbreaks Week (2009-03-03)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login